Fig. 3.

Spleen cells from docetaxel-treated tumor-bearing mice have cytotoxic effect on 4T1 tumor cells. A 24-h ⁵¹Cr release assay was done using 4T1 tumor cells as targets and T cells from tumor bearers, either treated or untreated with docetaxel in vivo. The T cells were purified using a commercial affinity column and were >95% pure. The percentage of specific ⁵¹Cr release was determined by the following equation: $(\text{experimental}\text{cpm}-\text{spontaneous}\text{cpm})/(\text{total}\text{cpm}\text{incorporated}-\text{spontaneous}\text{cpm})\times 100$. All determinations were done in triplicate, and the SEM of all assays was calculated and was typically 5% of the mean or less.